Literature DB >> 32553070

Severe Acute Respiratory Syndrome Coronavirus 2 among Asymptomatic Workers Screened for Work Resumption, China.

Xiaoyu Han, Xiong Wei, Osamah Alwalid, Yukun Cao, Yumin Li, Li Wang, Heshui Shi.   

Abstract

After the outbreak in Wuhan, China, we assessed 29,299 workers screened for severe acute respiratory syndrome coronavirus 2 by reverse transcription PCR. We noted 18 (0.061%) cases of asymptomatic infection; 13 turned negative within 8.0 days, and 41 close contacts tested negative. Among 6 contacts who had serologic tests, none were positive.

Entities:  

Keywords:  COVID-19; China; SARS; SARS-CoV-2; Wuhan; coronavirus; coronavirus disease; respiratory infections; severe acute respiratory syndrome coronavirus 2; viruses; zoonoses

Mesh:

Substances:

Year:  2020        PMID: 32553070      PMCID: PMC7454110          DOI: 10.3201/eid2609.201848

Source DB:  PubMed          Journal:  Emerg Infect Dis        ISSN: 1080-6040            Impact factor:   6.883


As the population of Wuhan, China, returns to work, asymptomatic cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being discovered among workers receiving health checkups for work resumption. Previous studies have shown that asymptomatic cases can be a public health threat and might lead to another outbreak (,). However, little is known about the clinical characteristics of asymptomatic infections. We report on cases of asymptomatic SARS-CoV-2 infection among persons during work resumption screening in Wuhan. At Wuhan Pingan Healthcare Diagnostic Center, we reviewed 29,299 asymptomatic persons who were screened for SARS-CoV-2 by reverse transcription PCR (RT-PCR) and 22,633 asymptomatic persons tested for SARS-CoV-2 antibodies during March 13–April 25, 2020. Throat swab specimens were tested for SARS-CoV-2 by using Real-Time Fluorescent-PCR Kits (DAAN GENE Co., LTD, https://www.en.daangene.com; Appendix). We used colloidal gold-based immunochromatographic strip assay, Novel Coronavirus (SARS-CoV-2) IgM/IgG Antibody Detection Assay (Vazyme Biotech Co. Ltd., http://vazyme.bioon.com.cn) to perform antibody testing (Appendix). We recorded the demographic features, exposure history, RT-PCR and serology results, and imaging reports at the time of testing. We obtained follow-up data from persons screened by telephone. Among 29,299 persons screened by RT-PCR, we confirmed 18 (0.061%) cases of SARS-CoV-2 infection. Of 22,633 persons tested for SARS-CoV-2 antibodies, 617 (2.7%) cases had positive IgG but negative IgM; 196 (0.87%) cases had positive IgG and IgM; and 40 (0.18%) cases had negative IgG but positive IgM. The median age of 18 asymptomatic case-patients (10 male, 8 female) was 30.5 years (Table). Six (33.3%) cases had clear contact history with a confirmed case of SARS-CoV-2 infection. The median cycle threshold (Ct) values on the day of first positive RT-PCR were 38.2 (Ct range 37.2–39.3) for ORFa1b gene and 38.1 (Ct range 36.81–38.5) for N gene (Table). All antibody tests were obtained on the day of first positive RT-PCR except in 1 case (obtained 6 days later). Half (7/14) the cases had negative IgM and IgG; the other half had positive IgG but negative IgM results (Table). Among 8 case-patients who had computed tomography imaging of the chest, none had remarkable findings. We closely observed the cases for 3–41 (median 16.5) days; 13 cases had negative RT-PCR within a median of 8 (range 3–14) days (Table), and none had symptoms. Among 41 close contacts, all had 2 consecutive negative RT-PCR tests >24 hours apart. Among 6 contacts who had serologic tests, none had positive results.
Table

Clinical characteristics of asymptomatic persons with detected severe acute respiratory syndrome coronavirus 2 infection, Wuhan, China*

Age, y/sexOccupation
Underlying conditionInterval, d†
Exposure
sourceRT-PCRCt ORFa1bCt NInterval, d‡IgMIgGChest CTInterval, d§Follow-up, d
29/MOffice workerN70Family+, –, –37385+Normal041
32/MJournalistN54Bus passenger+, +, –39389+Normal041
27/MJournalistNNAUnclear+, –35323Normal039
31/FResearcherN61Family+, –, –, –, –36387NANA23
27/MOffice workerN75Family+, –, –, –33353+Normal021
32/FHousewifeNNAUnclear+, –, –383714NANA17
37/FOffice workerN22Family+, –, –, –40398NANANANA16
57/MLogistics dispatcherAsthmaNAUnclear+, –, –39378NANANormal1016
25/MBankingNNAUnclear+, –, –38388NAANANA16
26/MMarketingNNAUnclear+3938NANANA17
23/MMarketingNNAUnclear+, –383813Normal517
26/FOffice workerNNAUnclear+, –384014NANANANA17
60/FCleanerNNAUnclear+3737NA+NANA13
65/MCleanerCOPDNAUnclear+3939NANormal013
28/FOffice workerNNAUnclear+3839NA+NANA8
33/FOffice workerN30Family+, –393712+Normal014
30/FOffice workerNNAUnclear+, –393810+NANA13
62/MWorkerHypertension
NAUnclear+3939NANANA3

*COPD, chronic obstructive pulmonary disease; CT, computed tomography; Ct ORFa1b, RT-PCR cycle threshold for the ORFa1b gene; Ct N, RT-PCR cycle threshold for the N gene; N, no; NA, not available; +, positive; –, negative.
†Days between last exposure and initial positive RT–PCR.
‡Days between first positive and first negative RT-PCR results
§Days between first positive RT-PCR and CT scan.

*COPD, chronic obstructive pulmonary disease; CT, computed tomography; Ct ORFa1b, RT-PCR cycle threshold for the ORFa1b gene; Ct N, RT-PCR cycle threshold for the N gene; N, no; NA, not available; +, positive; –, negative.
†Days between last exposure and initial positive RT–PCR.
‡Days between first positive and first negative RT-PCR results
§Days between first positive RT-PCR and CT scan. According to Wuhan Municipal Health Commission (), 275,400 RT-PCR tests were performed for universal screening during April 9–15, 2020. Among those, 182 (0.066%) asymptomatic persons were identified as SARS-Cov-2–positive, which is consistent with our study. Half the cases in our study showed negative IgM and IgG at the time of positive RT-PCR, suggesting recent infections (<14 days). Seven (50%) cases in our study had positive IgG but negative IgM, indicating a late stage infection, 4 of which had a long interval of exposure (30–75 days). In addition, 13 cases had negative RT-PCR assays <8 (range 3–14) days, suggesting a favorable prognosis for persons with asymptomatic infections. Epidemiologic, virologic, and modeling evidence support the possibility of SARS-CoV-2 transmission from persons who are presymptomatic (SARS-CoV-2 detected before symptoms onset) or asymptomatic (never develop symptoms) (). None of the 18 asymptomatic persons in our study developed symptoms. Recent reports showed that the viral load of SARS-CoV-2 infections in persons with no or mild symptoms was similar to the viral load of symptomatic patients (,), which could contribute to rapid transmissions (). However, other studies demonstrated that asymptomatic patients had a lower viral load than symptomatic and presymptomatic patients (,,), which might indicate less transmissibility from asymptomatic persons. The median cycle threshold values for the 18 cases were 38.2 for ORFa1b gene and 38.1 for the N gene, indicating a relatively low viral load. In addition, all 41 close contacts of the asymptomatic case-patients tested negative by RT-PCR. Possible explanations for this finding include that: the asymptomatic infected persons had relatively low viral load and were less infectious; that asymptomatic persons did not have clinical symptoms, such as sneezing or coughing, that could cause virus spread; and that, due to the strict isolation and preventive measures taken in Wuhan for >3 months, the population was generally protected from the spread of infection by mask-wearing and self-quarantine. Our report has limitations. Our sample size of asymptomatic cases is small, and follow-up was short. Recall bias of exposure history is another limitation; in the absence of clear symptom onset, asymptomatic persons might be less likely to accurately recall exposures than persons with symptoms. Finally, that the study took a place during the post-peak period of the epidemic in Wuhan, so contacts could have been seropositive already; those tested were seronegative, but most contacts did not have serologic testing. In conclusion, as the population returns to the workplace, asymptomatic SARS-CoV-2infected persons could be among workers. Although we did not detect transmission among 41 contacts of persons who were SARS-CoV-2–positive, such transmission cannot be excluded. Therefore, continued testing, self-quarantine, and mask-wearing should be encouraged to reduce the risk for additional outbreaks.

Appendix

Laboratory methods used to detect severe acute respiratory syndrome corona virus 2 antigens and antibodies among asymptomatic persons returning to work and their contacts in Wuhan, China.
  8 in total

1.  Covert coronavirus infections could be seeding new outbreaks.

Authors:  Jane Qiu
Journal:  Nature       Date:  2020-03-20       Impact factor: 49.962

2.  Association of Public Health Interventions With the Epidemiology of the COVID-19 Outbreak in Wuhan, China.

Authors:  An Pan; Li Liu; Chaolong Wang; Huan Guo; Xingjie Hao; Qi Wang; Jiao Huang; Na He; Hongjie Yu; Xihong Lin; Sheng Wei; Tangchun Wu
Journal:  JAMA       Date:  2020-05-19       Impact factor: 56.272

3.  Evidence Supporting Transmission of Severe Acute Respiratory Syndrome Coronavirus 2 While Presymptomatic or Asymptomatic.

Authors:  Nathan W Furukawa; John T Brooks; Jeremy Sobel
Journal:  Emerg Infect Dis       Date:  2020-06-21       Impact factor: 6.883

4.  Viral dynamics in asymptomatic patients with COVID-19.

Authors:  Rui Zhou; Furong Li; Fengjuan Chen; Huamin Liu; Jiazhen Zheng; Chunliang Lei; Xianbo Wu
Journal:  Int J Infect Dis       Date:  2020-05-11       Impact factor: 3.623

5.  The relative transmissibility of asymptomatic COVID-19 infections among close contacts.

Authors:  Daihai He; Shi Zhao; Qianying Lin; Zian Zhuang; Peihua Cao; Maggie H Wang; Lin Yang
Journal:  Int J Infect Dis       Date:  2020-04-18       Impact factor: 3.623

6.  SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients.

Authors:  Lirong Zou; Feng Ruan; Mingxing Huang; Lijun Liang; Huitao Huang; Zhongsi Hong; Jianxiang Yu; Min Kang; Yingchao Song; Jinyu Xia; Qianfang Guo; Tie Song; Jianfeng He; Hui-Ling Yen; Malik Peiris; Jie Wu
Journal:  N Engl J Med       Date:  2020-02-19       Impact factor: 91.245

7.  Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.

Authors:  Melissa M Arons; Kelly M Hatfield; Sujan C Reddy; Anne Kimball; Allison James; Jesica R Jacobs; Joanne Taylor; Kevin Spicer; Ana C Bardossy; Lisa P Oakley; Sukarma Tanwar; Jonathan W Dyal; Josh Harney; Zeshan Chisty; Jeneita M Bell; Mark Methner; Prabasaj Paul; Christina M Carlson; Heather P McLaughlin; Natalie Thornburg; Suxiang Tong; Azaibi Tamin; Ying Tao; Anna Uehara; Jennifer Harcourt; Shauna Clark; Claire Brostrom-Smith; Libby C Page; Meagan Kay; James Lewis; Patty Montgomery; Nimalie D Stone; Thomas A Clark; Margaret A Honein; Jeffrey S Duchin; John A Jernigan
Journal:  N Engl J Med       Date:  2020-04-24       Impact factor: 91.245

8.  Viral kinetics of SARS-CoV-2 in asymptomatic carriers and presymptomatic patients.

Authors:  Seong Eun Kim; Hae Seong Jeong; Yohan Yu; Sung Un Shin; Soosung Kim; Tae Hoon Oh; Uh Jin Kim; Seung-Ji Kang; Hee-Chang Jang; Sook-In Jung; Kyung-Hwa Park
Journal:  Int J Infect Dis       Date:  2020-05-04       Impact factor: 3.623

  8 in total
  2 in total

1.  Occurrence and transmission potential of asymptomatic and presymptomatic SARS-CoV-2 infections: Update of a living systematic review and meta-analysis.

Authors:  Diana Buitrago-Garcia; Aziz Mert Ipekci; Leonie Heron; Hira Imeri; Lucia Araujo-Chaveron; Ingrid Arevalo-Rodriguez; Agustín Ciapponi; Muge Cevik; Anthony Hauser; Muhammad Irfanul Alam; Kaspar Meili; Eric A Meyerowitz; Nirmala Prajapati; Xueting Qiu; Aaron Richterman; William Gildardo Robles-Rodriguez; Shabnam Thapa; Ivan Zhelyazkov; Georgia Salanti; Nicola Low
Journal:  PLoS Med       Date:  2022-05-26       Impact factor: 11.613

2.  Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Qiuyue Ma; Jue Liu; Qiao Liu; Liangyu Kang; Runqing Liu; Wenzhan Jing; Yu Wu; Min Liu
Journal:  JAMA Netw Open       Date:  2021-12-01
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.